| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0624fad8ca3d5f209b17107e9df6c4c5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2330-31 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2020-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a1ed5a1d39d751473d53cdcf3ac73ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cadb9fe2fde5e5307d0de02057b1354 |
| publicationDate |
2021-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
GB-2585278-A |
| titleOfInvention |
Apolipoprotein B Antagonist |
| abstract |
A nucleic acid molecule comprising a double stranded inhibitory RNA having a sense strand encoding a part of the human apolipoprotein B (Apo B) gene and a complementary antisense strand further comprises a single short DNA molecule covalently linked to the 3’ end of either of the sense or antisense strands which comprises a self-complementary section such that a hairpin DNA double stranded crook structure may form. Preferably the siRNA-DNA hybrid molecule is covalently linked to a targeting moiety such as N-acetylgalactosamine (GalNAc). A pharmaceutical composition comprising the siRNA construct is disclosed. The siRNA construct for the treatment or prevention of hypercholesterolaemia is disclosed. Evidence of the activity of the preferred GalNAc conjugated embodiment to reduce Apo-B expression in mice is disclosed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2604987-A |
| priorityDate |
2019-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |